Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Rallybio Corporation before investing.

In this article, we go over a few key elements for understanding Rallybio Corporation’s stock price such as:

• Rallybio Corporation’s current stock price and volume
• Why Rallybio Corporation’s stock price changed recently
• Upgrades and downgrades for RLYB from analysts
• RLYB’s stock price momentum as measured by its relative strength

About Rallybio Corporation (RLYB)

Before we jump into Rallybio Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Want to learn more about Rallybio Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Rallybio Corporation.

Rallybio Corporation’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Rallybio Corporation’s stock price was $16.925.

Rallybio Corporation is up 0.3% from its previous closing price of $16.875.

During the last market session, Rallybio Corporation’s stock traded between $16.750 and $17.010. Currently, there are approximately 5.70 million shares outstanding for Rallybio Corporation.

Rallybio Corporation’s price-earnings (P/E) ratio is currently at 2.1, which is low compared to the Biotechnology industry median of 20.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Rallybio Corporation Stock Price History

Rallybio Corporation’s (RLYB) price is currently up 0.8% so far this month.

During the month of September, Rallybio Corporation’s stock price has reached a high of $17.260 and a low of $16.650.

Over the last year, Rallybio Corporation has hit prices as high as $17.574 and as low as $3.670. Year to date, Rallybio Corporation’s stock is up 208.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Rallybio Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded Rallybio Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Rallybio Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Rallybio Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Rallybio Corporation’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Rallybio Corporation (RLYB) by visiting AAII Stock Evaluator.

Relative Price Strength of Rallybio Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Rallybio Corporation has a weighted four-quarter relative price strength of 29.43%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Rallybio Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Rallybio Corporation Stock Price: Bottom Line

As of September 4, 2026, Rallybio Corporation’s stock price is $16.925, which is up 0.3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Rallybio Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.